Immunomodulating compositions and methods of use thereof

Patent metadata

Field	Value
Publication number	US-9457047-B2
Application number	US-201314037420-A
Country	US
Kind code	B2
Filing date	Sep 26, 2013
Priority date	Nov 6, 2006
Publication date	Oct 4, 2016
Grant date	Oct 4, 2016

Abstract

This invention is directed to β-1-6-glucans, compositions and devices comprising the same, and methods of use thereof in modulating immune responses. The β-1-6-glucans of certain embodiments of the invention are enriched for O-acetylated groups and/or conjugated to a solid support or linked to a targeting moiety.

First claim

What is claimed is:

1. A composition comprising β-1-6-glucan linked to a targeting moiety, wherein the targeting moiety is selected from the group consisting of an engineered binding protein, an antibody, an antibody fragment, a nucleic acid, a peptide, and a small molecule, and wherein the targeting moiety specifically interacts with a neoplastic cell, a pre-neoplastic cell, a pathogen, or a component thereof.

2. The composition of claim 1 , wherein the targeting moiety specifically interacts with a pathogen or a component thereof.

3. The composition of claim 2 , wherein the composition enhances phagocytosis and/or cytotoxic responses to the pathogen.

4. The composition of claim 2 , wherein the composition enhances complement-mediated lysis of the pathogen.

5. The composition of claim 2 , wherein the composition enhances the immune response to the pathogen.

6. The composition of claim 2 , wherein the pathogen is a bacterium, virus, or parasite.

7. The composition of claim 1 , wherein the targeting moiety is a small molecule.

8. The composition of claim 1 , wherein the targeting moiety is a peptide.

9. The composition of claim 8 , wherein the peptide is a peptide which binds to a transmembrane molecule.

10. The composition of claim 8 , wherein the peptide is a naturally occurring peptide ligand for a receptor, or a modified form thereof.

11. The composition of claim 1 , wherein the targeting moiety is a nucleic acid.

12. The composition of claim 11 , wherein the nucleic acid is an aptamer.

13. The composition of claim wherein e targeting moiety is an engineered binding protein.

14. The composition of claim 1 , wherein the β-1-6-glucan is derived from a fungal glucan.

15. The composition of claim 1 , wherein the β-1-6-glucan is derived from pustulan.

16. The composition of claim 1 , wherein the β-1-6-glucan is derived from a fungal glucan via one or more processing steps that include hydrolysis and/or enzymatic digestion.

17. The composition of claim 1 , wherein the β-1-6-glucan is chemically synthesized.

18. The composition of claim 1 , wherein the β-1-6-glucan is genetically engineered.

19. The composition of claim 18 , wherein the β-1-6-glucan is synthesized in a bacteria, yeast, or mammalian cell.

20. The composition of claim 1 , wherein the β-1-6-glucan is soluble.

21. The composition of claim 1 , wherein the β-1-6-glucan comprises a structural modification selected from the group consisting of O-acetylation, methylation, alkylation, esterification, a tkoy iation, sulfation, phosphorylation, lipid conjugation and combinations thereof.

22. The composition of claim 1 , wherein the β-1-6-glucan has a molecular weight less than 100 kDa.

23. The composition of claim 1 , wherein the β-1-6-glucan contains fewer than 85 glucose monosaccharide units.

24. The composition of claim 1 , wherein the β-1-6-glucan contains 85, 84, 83, 82, 81, 80, 79, 78, 77, 76, 75, 74, 73, 72, 71, 70, 69, 68, 67, 66, or 65 glucose monosaccharide units.

25. The composition of claim 1 , wherein the β-1-6-glucan contains 64, 63, 62, 61, 60, 59, 58, 57, 56, 55, 54, 53, 52, 51, 50, 49, 48, 47, 46, 45, or 44 glucose monosaccharide units.

26. The composition of claim 1 , wherein the β-1-6-glucan contains 43, 42, 41, 40, 39, 38, 37, 36, 35, 34, 33, 32, 31, 30, 29, 28, 27, 26, 25, 24, or 23 glucose monosaccharide units.

27. The composition of claim 1 , wherein the β-1-6-glucan contains 22, 21, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, or 4 glucose monosaccharide units.

28. The composition of claim 1 , wherein at least 90% of the dry weight of glucan contained in the composition is β-1-6-glucan.

29. The composition of claim 1 , wherein less than 10% of the total glucan in the composition, by weight, is β-1-3-glucan.

30. The composition of claim 1 , wherein the composition is substantially free of β-1-3-glucan.

31. The composition of claim 1 , wherein the β-1-6-glucan is directly linked to the targeting moiety.

32. The composition of claim 1 , wherein the β-1-6-glucan is linked to the targeting moiety via a linker molecule.

33. The composition of claim 1 , wherein the β-1-6-glucan is linked to the targeting moiety via amide, urethane, imine or disulfide formation between the respective molecules, or between a linker molecule and the respective molecules.

34. The composition of claim 1 , wherein the targeting moiety targets a neoplastic cell, a pre-neoplastic cell or a component thereof.

35. The composition of claim 34 , wherein the targeting moiety targets a tumor antigen.

36. A composition comprising β-1-6-glucan comprising at least 4 and fewer than 50 glucose monosaccharide units linked to a targeting moiety, wherein the targeting moiety is selected from the group consisting of an engineered binding protein, an antibody, an antibody fragment, a nucleic acid, a peptide, and a small molecule, and wherein at least 95% of the dry weight of glucan contained in the composition is β-1-6-glucan.

37. A composition comprising soluble β-1-6-glucan linked to a targeting moiety, wherein the targeting moiety is selected from the group consisting of an engineered binding protein, an antibody, an antibody fragment, a nucleic acid, a peptide, and a small molecule, and wherein at least 95% of the dry weight of glucan contained in the composition is soluble β-1-6-glucan.

38. A composition comprising β-1-6-glucan comprising at least 4 and fewer than 50 glucose monosaccharide units linked to a targeting moiety, wherein the targeting moiety is selected from the group consisting of an engineered binding protein, an antibody, an antibody fragment, a nucleic acid, a peptide, and a small molecule, and wherein less than 5% of the total glucan in the composition, by weight, is β-1,3-glucan.

39. A composition comprising soluble β-1-6-glucan linked to a targeting moiety, wherein the targeting moiety is selected from the group consisting of an engineered binding protein, an antibody, an antibody fragment, a nucleic acid, a peptide, and a small molecule, and wherein less than 5% of the total glucan in the composition, by weight, is β-1,3-glucan.

Assignees

• Whitehead Biomedical Inst
• Massachusetts Inst Technology
• Univ Boston
• Massachusetts Gen Hospital
• Univ Boston

Inventors

• Rubin-Bejerano Ifat
• Fink Gerald R
• Abeijon Claudia
• Kohane Daniel S
• Fuller Jason E
• Langer Robert S

Classifications

• C08J2367/04

  Polyesters derived from hydroxy carboxylic acids, e.g. lactones (C08J2367/06 takes precedence) · CPC title

• C08J3/128

  Polymer particles coated by inorganic and non-macromolecular organic compounds · CPC title

• C08B37/0024

  beta-D-Glucans; (beta-1,3)-D-Glucans, e.g. paramylon, coriolan, sclerotan, pachyman, callose, scleroglucan, schizophyllan, laminaran, lentinan or curdlan; (beta-1,6)-D-Glucans, e.g. pustulan; (beta-1,4)-D-Glucans; (beta-1,3)(beta-1,4)-D-Glucans, e.g. lichenan; Derivatives thereof · CPC title

• A61K47/48538

  Human Necessities · mapped topic

• A61K31/716 Primary

  Glucans · CPC title